These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18171726)

  • 41. Aldosterone blockade after myocardial infarction.
    Hackam DG
    CMAJ; 2003 Sep; 169(5):444. PubMed ID: 12952808
    [No Abstract]   [Full Text] [Related]  

  • 42. [Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study].
    Watanabe J
    Nihon Rinsho; 2007 Apr; 65 Suppl 4():543-6. PubMed ID: 17508588
    [No Abstract]   [Full Text] [Related]  

  • 43. Aldosterone blockade in patients with systolic left ventricular dysfunction.
    Pitt B
    Circulation; 2003 Oct; 108(15):1790-4. PubMed ID: 14557343
    [No Abstract]   [Full Text] [Related]  

  • 44. Management of heart failure and left ventricular systolic dysfunction following acute myocardial infarction.
    Conti CR
    Clin Cardiol; 2005 Jan; 28(1):1-2. PubMed ID: 15704523
    [No Abstract]   [Full Text] [Related]  

  • 45. [New evidences on the use of aldosterone receptor antagonists in left ventricular dysfunction: from myocardial infarction to heart failure].
    Greco C; Castelli G; Crea F; Gavazzi A; Gensini GF; Scherillo M; Sinagra G
    G Ital Cardiol (Rome); 2012 Dec; 13(12):809-16. PubMed ID: 23196683
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Eplerenone in patients with left ventricular dysfunction.
    Coca SG; Buller GK
    N Engl J Med; 2003 Jul; 349(1):88-9; author reply 88-9. PubMed ID: 12846223
    [No Abstract]   [Full Text] [Related]  

  • 47. Aldosterone target organ protection by eplerenone.
    Rudolph AE; Rocha R; McMahon EG
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):229-38. PubMed ID: 15134822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure].
    Tereshchenko SN; Zhirov IV; Osmolovskaia IuF
    Ter Arkh; 2013; 85(12):137-43. PubMed ID: 24640683
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS).
    Chan PS; Soto G; Jones PG; Nallamothu BK; Zhang Z; Weintraub WS; Spertus JA
    Circulation; 2009 Jan; 119(3):398-407. PubMed ID: 19139382
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Letter regarding article by Weintraub et al, "Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure".
    Stecker EC; McAnulty JH
    Circulation; 2005 Aug; 112(5):e74. PubMed ID: 16061750
    [No Abstract]   [Full Text] [Related]  

  • 51. Integrating traditional and emerging treatment options in heart failure.
    Nolan PE
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S14-22. PubMed ID: 15160834
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aldosterone blockade and heart failure.
    Jessup M
    N Engl J Med; 2003 Apr; 348(14):1380-2. PubMed ID: 12668698
    [No Abstract]   [Full Text] [Related]  

  • 53. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.
    Rossignol P; Ménard J; Fay R; Gustafsson F; Pitt B; Zannad F
    J Am Coll Cardiol; 2011 Nov; 58(19):1958-66. PubMed ID: 22032706
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial.
    Iqbal J; Fay R; Adlam D; Squire I; Parviz Y; Gunn J; Pitt B; Zannad F
    Eur J Heart Fail; 2014 Jun; 16(6):685-91. PubMed ID: 24706498
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Heart failure after myocardial infarction. Increased risk, poorer treatment].
    MMW Fortschr Med; 2005 Dec; 147(48):67. PubMed ID: 16389866
    [No Abstract]   [Full Text] [Related]  

  • 56. Mineralocorticoid receptor antagonists: their use and differentiation in Japan.
    Sato A
    Hypertens Res; 2013 Mar; 36(3):185-90. PubMed ID: 23171954
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction.
    Weir RA; Tsorlalis IK; Steedman T; Dargie HJ; Fraser R; McMurray JJ; Connell JM
    Eur J Heart Fail; 2011 Dec; 13(12):1305-13. PubMed ID: 21940729
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of the selective aldosterone receptor blockers in arterial hypertension.
    Sierra C; Ruilope LM
    J Renin Angiotensin Aldosterone Syst; 2004 Mar; 5(1):23-5. PubMed ID: 15136969
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blocking aldosterone in heart failure.
    Shafiq MM; Miller AB
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):379-85. PubMed ID: 19661156
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective.
    Szucs TD; Holm MV; Schwenkglenks M; Zhang Z; Weintraub WS; Burnier M; Erne P
    Cardiovasc Drugs Ther; 2006 Jun; 20(3):193-204. PubMed ID: 16775667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.